SBRA posts Q3 2025 results press release and exhibits

Q: Which exhibits were included in SBRA’s filing?

The filing includes Ex. 99.1 (press release), Ex. 99.2 (supplemental information package), Ex. 99.3 (non-GAAP reconciliations), and Ex. 99.4 (investor presentation).

Q: Are SBRA’s Q3 2025 materials filed or furnished?

They are furnished, not filed , under Items 2.02 and 7.01 and are not subject to Section 18 liabilities.

Q: Where can investors access SBRA’s reconciliations and supplemental data?

They are available on Sabra’s Investors section at www.sabrahealth.com, free of charge.

Q: What period does SBRA’s press release cover?

It covers the company’s results for the three months ended September 30, 2025 .

Q: Who signed SBRA’s report?

The report was signed by Michael Costa , Chief Financial Officer, Secretary and Executive Vice President.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Sabra Health Care REIT (SBRA) furnished materials reporting results for the three months ended September 30, 2025. The company provided a press release (Ex. 99.1), a supplemental information package (Ex. 99.2), non-GAAP reconciliations (Ex. 99.3), and an investor presentation (Ex. 99.4). These Items 2.02 and 7.01 materials are furnished, not filed, and the reconciliations and supplemental data are also available on Sabra’s investor website.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 04:06 PM

FAQ

What did SBRA announce in its 8-K?

SBRA furnished materials reporting results for the three months ended September 30, 2025, including a press release, supplemental package, non-GAAP reconciliations, and an investor presentation.

Which exhibits were included in SBRA’s filing?

The filing includes Ex. 99.1 (press release), Ex. 99.2 (supplemental information package), Ex. 99.3 (non-GAAP reconciliations), and Ex. 99.4 (investor presentation).

Are SBRA’s Q3 2025 materials filed or furnished?

They are furnished, not filed, under Items 2.02 and 7.01 and are not subject to Section 18 liabilities.

Where can investors access SBRA’s reconciliations and supplemental data?

They are available on Sabra’s Investors section at www.sabrahealth.com, free of charge.

What period does SBRA’s press release cover?

It covers the company’s results for the three months ended September 30, 2025.

Who signed SBRA’s report?

The report was signed by Michael Costa, Chief Financial Officer, Secretary and Executive Vice President.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 5, 2025

SABRA HEALTH CARE REIT, INC.

(Exact name of registrant as specified in its charter)

Maryland

001-34950

27-2560479

(State of
Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

1781 Flight Way

Tustin

92782

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (888) 393-8248

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	SBRA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02			Results of Operations and Financial Condition.

On November 5, 2025, Sabra Health Care REIT, Inc. (“Sabra”) issued a press release reporting its results of operations for the three month period ended September 30, 2025. The press release refers to the Reconciliations of Non-GAAP Financial Measures that is available on the Investors section of Sabra’s website, free of charge, at www.sabrahealth.com. The text of the press release and the Reconciliations of Non-GAAP Financial Measures are furnished herewith as Exhibits 99.1 and 99.3, respectively, and are specifically incorporated by reference herein.


Item 7.01			Regulation FD Disclosure.

The press release furnished herewith as Exhibit 99.1 refers to a supplemental information package that is available on the Investors section of Sabra’s website, free of charge, at www.sabrahealth.com. The text of the supplemental information package is furnished herewith as Exhibit 99.2 and is specifically incorporated by reference herein.

Sabra intends to present the materials attached to this report as Exhibit 99.4 in investor presentations. The furnishing of these materials is not intended to constitute a representation that such furnishing is required by Regulation FD or other securities laws, or that the presentation materials include material investor information that is not otherwise publicly available. In addition, Sabra does not assume any obligation to update such information in the future.

The information in Items 2.02 and 7.01 of this Form 8-K and the information in Exhibits 99.1, 99.2, 99.3 and 99.4 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference into any filing of Sabra under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in any such filing.


Item 9.01			Financial Statements and Exhibits.


(d)						Exhibits.

99.1						Press Release of Sabra Health Care REIT, Inc., dated November 5, 2025.

99.2						Sabra Health Care REIT, Inc. Supplemental Information Package, dated September 30, 2025.

99.3						Reconciliations of Non-GAAP Financial Measures, dated September 30, 2025.

99.4						Investor Presentation.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	SABRA HEALTH CARE REIT, INC.

Date: November 5, 2025	/S/ MICHAEL COSTA
	Name:	Michael Costa
	Title:	Chief Financial Officer, Secretary and Executive Vice President

Source: View Original Filing on SEC EDGAR